Clinical Trial Update: Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 [Phase 1]

View source ↗

Summary

Phase 1 study assessing adverse events and change in disease activity in adults with select advanced solid tumors treated with ABBV-400; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Hormone Receptor-positive Breast Cancer
• Pancreatic Ductal Adenocarcinoma
• Platinum-resistant High-grade Epithelial Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ABBV-400

Snippet

Sponsor: AbbVie | Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING